Pay in 4 interest-free payments of $6.18 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
This highlights the need to consider the risks and benefits of these medications
Methods We obtained the data from PubMed, Scopus, Embase, and Web of Science for all eligible studies, including clinical trials (RCT) and cohorts comparing GLP-1 RAs to placebo or other hypoglycemic agents in patients with HFpEF published until December 31st, 2024
2024 [Epub ahead of print].
Secondary outcome measures were acute myocardial infarction (ICD-10: I21), stroke (cerebral infarction or nontraumatic intracerebral hemorrhage) (ICD-10: I61, I63), or acute heart failure (ICD-10: I50.21, I50.23, I50.31, I50.33, I50.41, I50.43, I50.811, I50.813)
For mild cold symptoms without gastrointestinal involvement, most people can safely continue their GLP-1 medication
CV 23977728 (Elk + Elk)
US$ 24.93
US$ 20.95
US$ 25.48
US$ 21.30
US$ 20.58
US$ 22.17
US$ 21.77
US$ 27.20
US$ 26.15
US$ 27.97
US$ 24.09
US$ 20.19
